Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases.
Nucl Med Mol Imaging
; 58(3): 113-119, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38633284
ABSTRACT
Purpose:
The objective of this study was to evaluate whether uptake on 18F-fluorodeoxyglucose (18F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases.Methods:
In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast cancer brain metastases, we analyzed both preoperative 18F-FDG PET/CT and HER2 status of the resected/biopsied brain specimens. The maximum standardized uptake values (SUVmax) of the lesions were normalized to contralateral normal white matter and compared using Mann-Whitney U tests.Results:
The study cohort was comprised of 12 women with breast cancer with a mean age of 59 years (range 43-76 years) with a total of 14 distinct brain metastatic lesions. The SUVmax ratio of HER2-positive breast cancer brain metastases was significantly greater than that of HER2-negative lesions (3.98 vs 1.79, U = 38.00, p = 0.008).Conclusion:
The SUVmax ratio may help to identify the HER2 status of breast cancer brain metastases, if validated prospectively.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Nucl Med Mol Imaging
Año:
2024
Tipo del documento:
Article